Table 3 |
||
|
Structural disease progression in patients with early RA who received DMARDs and the entire ESPOIR cohort. |
||
|
SD-treated patients |
All ESPOIR patients |
|
|
|
||
|
All patients |
(number = 370) |
(number = 736a) |
|
- ΔvSHS total |
1.6 ± 5.5 (0) |
0.96 ± 4.4 (0) |
|
- ΔvSHS erosion |
1.5 ± 4.7 (0) |
0.96 ± 3.8 (0) |
|
- ΔvSHS narrowing |
0.2 ± 1.8 (0) |
0.01 ± 1.81 (0) |
|
Patients with structural progressionb |
(number = 126, 34.1%) |
(number = 187, 25.4%) |
|
- ΔvSHS total |
5.4 ± 7.0 [54] |
5.0 ± 6.3 [54] |
|
- ΔvSHS ≥ 5 points (RRP) |
41 (11.1%) |
58 (7.9%) |
|
|
||
|
Data are mean ± SD (median) or number (%).aX-ray data were available for only 736 patients; bStructural progression was defined as ΔvSHS ≥ 1 point (that is, the smallest detectable difference). DMARD, disease-modifying anti-rheumatic drugs; RRP, rapid radiographic progression; SD, synthetic DMARD; ΔvSHS, change in van der Heijde-modified Sharp score. |
||
|
Fautrel et al. Arthritis Research & Therapy 2012 14:R249 doi:10.1186/ar4092 |
||
